Примери за използване на Lead to increases на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Nevertheless, TRIM could lead to increases or decreases in the capital needs of banks.
Gary Vaynerchuk talks frequently about how building those social,non-monetary relationships lead to increases in sales.
Nevertheless, TRIM could lead to increases or decreases in the own funds needs of individual banks.
In another study, NOAA scientists found that desert dust,which contains iron, deposited into the ocean from the atmosphere could lead to increases of harmful bacteria in the seawater.
New ideas that arise during the working day lead to increases in quality, efficiency and job satisfaction.
Conversely, concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium levels(e.g. potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, heparin)may lead to increases in serum potassium.
As we said above,this peptide acts on pulses that lead to increases in your body's natural secretion of growth hormone.
Concomitant use of Atacand Plus and potassium-sparing diuretics, potassium supplements or salt substitutes or other medicinal products that may increase serum potassium levels(e.g. heparin sodium)may lead to increases in serum potassium.
Co-administration of efavirenz andatazanavir in combination with ritonavir may lead to increases in efavirenz exposure which may worsen the tolerability profile of efavirenz.
Concomitant use of Atacand with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels(e.g. heparin)may lead to increases in serum potassium in hypertensive patients.
Potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels( e. g. heparin)may lead to increases in serum potassium and is, therefore, not recommended( see section 4.4).
Based on experience with the use of other substances that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other substances that may increase serum potassium levels(e.g. heparin)may lead to increases in serum potassium.
Based on the experience with the use of other medicinal products that blunt the renin-angiotensin system,concomitant use of the above medicinal products may lead to increases in serum potassium and is, therefore, not recommended see section.
Conversely, based on experience with the use of other medicinal products that blunt the renin-angiotensin system(RAS), concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels(e. g. heparin sodium)may lead to increases in serum potassium.
Concomitant use of potassium-sparing diuretics(triamterene, amiloride), mineralocorticoid antagonists(e.g. spironolactone, eplerenone), potassium supplements, salt substitutes containing potassium or other agents(such as heparin)may lead to increases in serum potassium, and to increases in serum creatinine.
Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels(e. g. heparin sodium)may lead to increases in serum potassium.
Based on experience with the use of other medicinal products that affect the RAAS, concomitant use of Edarbi with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels(e.g. heparin)may lead to increases in serum potassium in hypertensive patients(see section 4.5).
As with other medicinal products that block angiotensin II or its effects, concomitant use of other medicinal products which retain potassium(e.g. potassium-sparing diuretics: amiloride, triamterene, spironolactone) or may increase potassium levels(e.g. heparin), potassium supplements orsalt substitutes containing potassium may lead to increases in serum potassium.
Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels(e.g. heparin)may lead to increases in serum potassium and is, therefore, not recommended(see section 4.4).
Potassium supplements and potassium-sparing diuretics Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels(e.g. heparin)may lead to increases in serum potassium and is, therefore, not recommended(see section 4.4).
Potassium supplements and potassium-sparing diuretics: based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels(e.g. heparin)may lead to increases in serum potassium and is, therefore, not recommended(see section 4.4).
Proper planning and layout will lead to increased organization and comfort for the staff.
Decreased platelets lead to increased bleeding, in severe cases, bleeding develops.
Craniosynostosis can lead to increased intracranial pressure.
The market mechanisms lead to increasing prices if demand exceeds supply and vice versa.
Strong inhibitors of P-gp may lead to increased talazoparib exposure.
Unmet needs can lead to increased social activity.
Both lead to increased fuel consumption.
Economic hardship among vulnerable groups could lead to increased drug consumption.
Oxidation can lead to increased oil viscosity, which negatively affects energy efficiency.